文献速递血栓与止血

血小板靶向凝血因子VIII基因治疗在甲型血友病小鼠中诱导的免疫耐受由CD4 T细胞介导

Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
PubMed 文献 · J Thromb Haemost · 2017-09-11

本研究在FVIIInull小鼠中通过2bF8慢病毒载体转导和移植实现血小板-FVIII表达,无需体内筛选即可恢复止血并诱导免疫耐受;经660 cGy照射或白消安联合ATG预处理的小鼠在rhF8攻击后均未产生抗FVIII抑制性抗体,耐受可转移且由CD4+ T细胞介导。

要点

  • 2bF8LV基因治疗无需体内筛选即可在FVIIInull小鼠中持续表达血小板-FVIII并纠正出血素质。
  • 经660 cGy照射或白消安联合ATG预处理的小鼠在rhF8攻击后均未产生抗FVIII抑制性抗体。
  • 转导受体Treg细胞显著增加,免疫耐受可转移,CD4+ T细胞对rhF8再刺激不增殖。

核心结论

  • 2bF8LV基因转移无需对处理细胞进行体内筛选即可在甲型血友病小鼠中诱导免疫耐受,且该免疫耐受由CD4+ T细胞介导。

研究设计与样本

  • 研究采用2bF8慢病毒载体转导和移植引入血小板-FVIII表达,以FVIII检测和尾出血试验确认基因治疗成功,用rhF8攻击探索免疫耐受诱导,并通过Treg细胞分析、T细胞增殖试验和记忆B细胞ELISPOT试验探讨机制。

主要发现

  • 2bF8LV基因治疗后FVIIInull小鼠血小板-FVIII表达持续且出血素质得到纠正。
  • 经660 cGy照射或白消安联合ATG预处理组的转导受体在rhF8攻击后均未产生抗FVIII抑制性抗体。
  • 2bF8LV转导受体中Treg细胞显著增加,所诱导的免疫耐受可转移。
  • 来自治疗动物的CD4+ T细胞对rhF8再刺激不增殖,但2bF8LV转导受体中记忆B细胞可分化为抗体分泌细胞。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials The immune response is a significant concern in gene therapy. Platelet-targeted gene therapy can restore hemostasis and induce immune tolerance. CD4 T cell compartment is tolerized after platelet gene therapy. Preconditioning regimen affects immune tolerance induction in platelet gene therapy. SUMMARY: Background Immune responses are a major concern in gene therapy. Our previous studies demonstrated that platelet-targeted factor VIII (FVIII) (2bF8) gene therapy together with in vivo drug selection of transduced cells can rescue the bleeding diathesis and induce immune tolerance in FVIIInull mice. Objective To investigate whether non-selectable 2bF8 lentiviral vector (LV) for the induction of platelet-FVIII expression is sufficient to induce immune tolerance and how immune tolerance is induced after 2bF8LV gene therapy. Methods Platelet-FVIII expression was introduced by 2bF8LV transduction and transplantation. FVIII assays and tail bleeding tests were used to confirm the success of platelet gene therapy. Animals were challenged with rhF8 to explore if immune tolerance was induced after gene therapy. Treg cell analysis, T-cell proliferation assay and memory B-cell-mediated ELISPOT assay were used to investigate the potential mechanisms of immune tolerance. Results We showed that platelet-FVIII expression was sustained and the bleeding diathesis was restored in FVIIInull mice after 2bF8LV gene therapy. None of the transduced recipients developed anti-FVIII inhibitory antibodies in the groups preconditioned with 660 cGy irradiation or busulfan plus ATG treatment even after rhF8 challenge. Treg cells significantly increased in 2bF8LV-transduced recipients and the immune tolerance developed was transferable. CD4+ T cells from treated animals failed to proliferate in response to rhF8 re-stimulation, but memory B cells could differentiate into antibody secreting cells in 2bF8LV-transduced recipients. Conclusion 2bF8LV gene transfer without in vivo selection of manipulated cells can introduce immune tolerance in hemophilia A mice and this immune tolerance is CD4+ T cell mediated.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Chen Y, Luo X, Schroeder JA, et al. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated. J Thromb Haemost. 2017. PMID: 28799202. doi:10.1111/jth.13800

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。